4.5 Article

A prime-boost vaccination protocol optimizes immune responses against the nucleocapsid protein of the SARS coronavirus

Journal

VACCINE
Volume 26, Issue 51, Pages 6678-6684

Publisher

ELSEVIER SCI LTD
DOI: 10.1016/j.vaccine.2008.09.006

Keywords

SARS; Modified Vaccinia virus Ankara; Adjuvant; Mucosal immunization; Prime boost

Funding

  1. Bayerische Forschungsstiftung [PIZ 26/03]
  2. Friedrich-Schiedel-Stiftung of the Technical University Munich [5110095 TG 04]

Ask authors/readers for more resources

Severe acute respiratory syndrome (SARS) is a Serious infectious disease Caused by the SARS coronavirus. We assessed the potential of prime-boost vaccination protocols based oil the nucleocapsid (NC) protein co-administered with a derivative of the mucosal adjuvant MALP-2 or expressed by modified Vaccinia virus Ankara (MVA-NC) to stimulate humoral and cellular immune responses at systemic and mucosal levels. The obtained results demonstrated that strong immune responses can be elicited both at systemic and mucosal levels following a heterologous prime-boost vaccination protocol consisting in pruning with NC protein add-mixed with MALP-2 by intranasal route and boosting with MVA-NC by intramuscular route. (C) 2008 Published by Elsevier Ltd.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available